HomeCompareBKGM vs ABBV

BKGM vs ABBV: Dividend Comparison 2026

BKGM yields 3.02% · ABBV yields 3.09%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $30.2K in total portfolio value
10 years
BKGM
BKGM
● Live price
3.02%
Share price
$8,110.00
Annual div
$245.00
5Y div CAGR
36.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73.5K
Annual income
$18,748.22
Full BKGM calculator →
ABBV
AbbVie Inc.
● Live price
3.09%
Share price
$214.96
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$103.7K
Annual income
$25,324.79
Full ABBV calculator →

Portfolio growth — BKGM vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBKGMABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BKGM + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BKGM pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BKGM
Annual income on $10K today (after 15% tax)
$256.78/yr
After 10yr DRIP, annual income (after tax)
$15,935.99/yr
ABBV
Annual income on $10K today (after 15% tax)
$262.96/yr
After 10yr DRIP, annual income (after tax)
$21,526.07/yr
At 15% tax rate, ABBV beats the other by $5,590.08/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BKGM + ABBV for your $10,000?

BKGM: 50%ABBV: 50%
100% ABBV50/50100% BKGM
Portfolio after 10yr
$88.6K
Annual income
$22,036.50/yr
Blended yield
24.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

BKGM
No analyst data
Altman Z
-0.5
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+19.2% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BKGM buys
0
ABBV buys
0
No recent congressional trades found for BKGM or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBKGMABBV
Forward yield3.02%3.09%
Annual dividend / share$245.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR36.4%40.6%
Portfolio after 10y$73.5K$103.7K
Annual income after 10y$18,748.22$25,324.79
Total dividends collected$47.8K$62.2K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: BKGM vs ABBV ($10,000, DRIP)

YearBKGM PortfolioBKGM Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,112$412.06$11,555$434.96$443.00ABBV
2$12,474$583.69$13,485$635.47$1.0KABBV
3$14,182$835.24$15,933$937.67$1.8KABBV
4$16,385$1,210.57$19,118$1,400.80$2.7KABBV
5$19,315$1,782.94$23,384$2,125.24$4.1KABBV
6$23,347$2,679.24$29,290$3,286.81$5.9KABBV
7$29,109$4,128.24$37,776$5,205.38$8.7KABBV
8$37,708$6,561.47$50,495$8,488.44$12.8KABBV
9$51,183$10,835.25$70,497$14,346.44$19.3KABBV
10$73,514$18,748.22$103,718$25,324.79$30.2KABBV

BKGM vs ABBV: Complete Analysis 2026

BKGMStock

BankGuam Holding Company operates as the bank holding company for the Bank of Guam that provides various banking products and services to individuals, businesses, and government entities. It accepts various deposit products, including demand deposits, savings and time certificate of deposits, checking accounts, interest-bearing transaction accounts, time deposits, and retirement accounts for retail and business banking markets. The company also offers commercial loans, which comprise loans to governments primarily in commercial real estate, multifamily rentals, hotel, and gas stations, as well as in working capital and equipment financing; industrial, commercial, real estate, construction, and small business administration-guaranteed loans; home mortgage and home equity loans; and consumer loans for financing automobiles, various consumer goods, and other personal purposes. In addition, it provides trade financing and trust services; and credit life, health, auto, and homeowners insurance services as agents for various insurance companies. Further, the company offers wire and automated clearing house transfers, cashier's and traveler's checks, corporate and consumer credit cards, bank-by-mail, ATMs, night depositories, safe deposit boxes, direct deposits, electronic funds transfers, online banking and bill payments, merchant, check imaging, and other customary banking services. It operates a network of 17 full service branches, including 7 in Guam; one in Saipan and one each in Tinian and Rota, which are located in the Commonwealth of the Northern Mariana Islands; one in the Republic of Palau; one each in the states of Yap, Chuuk, Pohnpei, and Kosrae in the Federated States of Micronesia; one in the Republic of the Marshall Islands; and one in San Francisco, California. The company also operates ATMs at seventy-nine locations. BankGuam Holding Company was incorporated in 1972 and is headquartered in Hagåtña, Guam..

Full BKGM Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this BKGM vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BKGM vs SCHDBKGM vs JEPIBKGM vs OBKGM vs KOBKGM vs MAINBKGM vs JNJBKGM vs MRKBKGM vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.